Sep 25, 2026 · 4 min
European stocks split as UBS weighs capital rules and HelloFresh cuts forecasts
UBS Rises, Novo Climbs, HelloFresh Plummets
The episode shows how regulatory uncertainty, weaker guidance, and drug-development deals are driving sharply different outcomes across European markets.
- 1UBS rose as it considered strategic options amid possible stricter Swiss capital requirements.
- 2HelloFresh plunged after lowering its full-year sales and earnings forecasts.
- 3Novo Nordisk advanced on a potentially €1.165 billion Nanexa deal for longer-lasting obesity treatments.
Don't miss
HelloFresh’s plunge after cutting its full-year sales and earnings forecasts is the episode’s clearest market shock.
The brief
European stocks moved in sharply different directions as HelloFresh cut its outlook, UBS weighed regulatory options, and Novo Nordisk advanced on a treatment deal.
UBS rose while considering strategic changes amid possible stricter Swiss capital requirements, putting regulation and jurisdiction at the center of its move.
HelloFresh plunged after reducing its full-year sales and earnings forecasts, making weaker guidance the clearest negative signal in the report.
Novo Nordisk climbed after a potentially €1.165 billion agreement with Nanexa focused on longer-lasting obesity treatments, adding deal momentum to the session.
Together, the movers show how forecasts, capital rules, and product strategy can pull major European shares in opposite directions on the same day.
What was said on this episode
9 statements · 3 positive · 6 negative
HelloFresh’s outlook confirms soft trends and implies future weakness.
“it follows soft trends, confirms these soft trends, infers weakness ahead”
Listen at 0:57
HelloFresh shares reached a record low and fell as much as 13%.
“So shares hit a record low this morning. They're down as much as 13% this morning.”
Listen at 1:03
UBS may face stricter capital rules in Switzerland.
“they're facing the possibility of stricter capital rules at home in Switzerland”
Listen at 1:25
The endorsed Swiss plan would force UBS to hold more equity capital.
“would force UBS to hold more equity capital”
Listen at 1:34
The plan would require UBS to hold an additional $16 billion in equity capital.
“it would require it to hold an extra $16 billion, um, in that capital”
Listen at 1:38
UBS shares rose about 2.5% following the jurisdiction report.
“but its shares have risen on the back of that, up, um, about 2.5% this morning”
Listen at 2:06
Nanexa’s technology could reduce obesity injections to one every few months.
“technology that could mean that patients need just one obesity shot every few months rather than the more regular occurrence now”
Listen at 2:28
Nanexa shares jumped 161% after the Novo Nordisk deal.
“Nanexa shares obviously jumped. This is a big deal for them. They've jumped 161%.”
Listen at 2:35
The Nanexa deal is unlikely to trigger Novo Nordisk’s price in the short term.
“it's unlikely to be a short-term trigger for their price”
Listen at 2:53
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
UBSListen to the full episode and explore every guest, topic, and moment on PodLume.